Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.43 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 3/20 | 0.39 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.39 |
| ▸ | CTSD | P07339 | 1/20 | 0.39 |
| ▸ | CTSE | P14091 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103996 | 0.87 | ALDH1A1 (0.51) | KMT2AGPR119CTSDCTSEBACE1 | |
| SCHEMBL3925930 | 0.86 | RORC (0.48) | MEN1KMT2ARORC | |
| SCHEMBL22509312 | 0.84 | OPRM1 (0.55) | MEN1KMT2AGPR119 | |
| SCHEMBL3396946 | 0.83 | GPR119 (0.54) | MEN1KMT2AGPR119LIPEEPHX2 | |
| SCHEMBL3160806 | 0.83 | OPRM1 (0.56) | GPR119 | |
| SCHEMBL651457 | 0.83 | OPRM1 (0.56) | MEN1KMT2A | |
| SCHEMBL1938611 | 0.83 | RORC (0.48) | GPR119RORC | |
| SCHEMBL2529921 | 0.83 | CA12 (0.54) | GPR119TACR1 | |
| SCHEMBL16553809 | 0.83 | ATM (0.43) | GPR119TACR1 | |
| SCHEMBL16553802 | 0.83 | JAK2 (0.50) | MEN1KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| EP-2029592-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007125325-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016340-A1 | PHARMACEUTICAL COMPOUNDS | PKN2, PKN1, CSNK1A1 | MEN1 484/4885KMT2A 3188/4885GPR119 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.